DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Peters S. et al.
Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026 [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR;
Cancer Res 2017;
77 (Suppl. 13) Abstract nr CT082
DOI: 10.1158/1538-7445.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.